Table 5.
Characteristics of experimental drugs affecting HDL.
| Drug | Effect | Tested Subjects | |
|---|---|---|---|
| ApoJ mimetic peptides | ↑RCT, ↓lipoprotein lipid peroxides, ↑PON1, improved anti-inflammatory HDL function | Mice, monkeys | [594,595] |
| ApoC-II mimetic peptides | ↑ABCA1-mediated cholesterol efflux | mice | [596,597] |
| Antisense oligonucleotides | altering expression of specific genes (CETP) | mice | [598] |
| inhibiting miRNAs involved in HDL metabolism and function (miR-33 a/b) | primate, mice | [599,600] | |
| SR-B1 inhibitors | ↓SR-B1-mediated uptake of HDL to liver → ↑HDLc | Humans, mice | [443,601] |
| Hydrogen-rich water | ↓Lp-PLA2, ↑LCAT, antioxidant activity (↑PON1) → improved HDL function, ↑CEC | humans, rats, hamsters | [603,604] |
| Purified sardine proteins | ↑LCAT → ↑RCT, ↑PON1 → ↓HDL oxidation | rats | [605,606] |
| Photodynamic therapy with photosensitisers | ↑ABCA1-mediated cholesterol eflux | rabbits, mice | [610,611] |